This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2001 Sep;108(5):641-4.

doi: 10.1172/JCI13885.

The experimental use of antisense oligonucleotides: a guide for the perplexed

C A Stein¹

Affiliations

PMID: 11544265
PMCID: PMC209389
DOI: 10.1172/JCI13885

The experimental use of antisense oligonucleotides: a guide for the perplexed

C A Stein. J Clin Invest. 2001 Sep.

. 2001 Sep;108(5):641-4.

doi: 10.1172/JCI13885.

Author

C A Stein¹

Affiliation

¹ Columbia University, 630 West 168 Street, New York, New York 10032, USA. stein@cuccfa.ccc.columbia.edu

PMID: 11544265
PMCID: PMC209389
DOI: 10.1172/JCI13885

No abstract available

PubMed Disclaimer

Similar articles

Prediction of VEGF mRNA antisense oligodeoxynucleotides by RNA structure software and their effects on HL60 and K562 cells.
Fei J, Zhang Y. Fei J, et al. Cell Biol Int. 2005 Sep;29(9):737-41. doi: 10.1016/j.cellbi.2005.04.009. Cell Biol Int. 2005. PMID: 15985377
CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
Nesterova MV, Johnson NR, Stewart T, Abrams S, Cho-Chung YS. Nesterova MV, et al. Clin Cancer Res. 2005 Aug 15;11(16):5950-5. doi: 10.1158/1078-0432.CCR-05-0624. Clin Cancer Res. 2005. PMID: 16115938
Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
Takagi-Sato M, Tokuhiro S, Kawaida R, Koizumi M. Takagi-Sato M, et al. Nucleic Acids Symp Ser (Oxf). 2006;(50):319-20. doi: 10.1093/nass/nrl159. Nucleic Acids Symp Ser (Oxf). 2006. PMID: 17150946
How to design an antisense oligodeoxynucleotide experiment: a consensus approach.
Stein CA. Stein CA. Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):129-32. doi: 10.1089/oli.1.1998.8.129. Antisense Nucleic Acid Drug Dev. 1998. PMID: 9593051 Review. No abstract available.
[Antisense strategy--new trends].
Koziołkiewicz M. Koziołkiewicz M. Postepy Biochem. 1998;44(2):125-35. Postepy Biochem. 1998. PMID: 9770236 Review. Polish. No abstract available.

See all similar articles

Cited by

Targeting long non-coding RNA to therapeutically upregulate gene expression.
Wahlestedt C. Wahlestedt C. Nat Rev Drug Discov. 2013 Jun;12(6):433-46. doi: 10.1038/nrd4018. Nat Rev Drug Discov. 2013. PMID: 23722346 Review.
Antisense oligonucleotides: A primer.
Scoles DR, Minikel EV, Pulst SM. Scoles DR, et al. Neurol Genet. 2019 Apr 1;5(2):e323. doi: 10.1212/NXG.0000000000000323. eCollection 2019 Apr. Neurol Genet. 2019. PMID: 31119194 Free PMC article. Review.
Determination of RNase H activity via real-time monitoring of target-triggered rolling circle amplification.
Lee CY, Kang KS, Park KS, Park HG. Lee CY, et al. Mikrochim Acta. 2017 Dec 14;185(1):53. doi: 10.1007/s00604-017-2610-8. Mikrochim Acta. 2017. PMID: 29594533
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.
Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Bates PJ, et al. Exp Mol Pathol. 2009 Jun;86(3):151-64. doi: 10.1016/j.yexmp.2009.01.004. Epub 2009 Jan 20. Exp Mol Pathol. 2009. PMID: 19454272 Free PMC article. Review.
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.
Shen X, Corey DR. Shen X, et al. Nucleic Acids Res. 2018 Feb 28;46(4):1584-1600. doi: 10.1093/nar/gkx1239. Nucleic Acids Res. 2018. PMID: 29240946 Free PMC article. Review.

See all "Cited by" articles

References

1. Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994;4:67–69. - PubMed
1. Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988;16:3209–3221. - PMC - PubMed
1. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem. 1995;270:2620–2627. - PubMed
1. Fennewald SM, Rando RF. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem. 1995;270:21718–21721. - PubMed
1. Rockwell P, et al. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA. 1997;94:6523–6528. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database